Scientific research company IAVI, the Serum Institute of India Pvt Ltd, India and Merck KGaA, Darmstadt, Germany on Thursday signed a partnership for the co development of neutralizing monoclonal antibodies (mAbs) in the fight against the COVID-19 pandemic.
The collaboration will leverage each partner's remarkable expertise, geographic presence and infrastructure to develop the neutralizing monoclonal antibodies neutralizing to fight COVID-19 and ensure timely and equitable global access.
Unique among the various agreements for the development of monoclonal antibodies to fight COVID-19, the partnership is aimed at ensuring access to a class of innovative therapies that, so far, have been out of reach of low and middle countries income.
In addition, the neutralizing monoclonal antibodies (mAbs) are reportedly co-invented by IAVI and Scripps Research. The partners are committed in developing an anti-COVID-19 treatment, with equal global access as the primary goal.
Lilly declares Q2 2025 dividend
Bruker acquires majority stake in RECIPE to expand clinical mass spectrometry diagnostics
Emmaus Life Sciences reports drop in revenues, increased loss in 2024
L'Oréal and WHO Foundation partner to expand global skin health access